These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23303667)

  • 21. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
    Douni E; Rinotas V; Makrinou E; Zwerina J; Penninger JM; Eliopoulos E; Schett G; Kollias G
    Hum Mol Genet; 2012 Feb; 21(4):784-98. PubMed ID: 22068587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
    Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
    Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of TNF-α, GSK-3β and RANKL in the occurrence and development of diabetic osteoporosis.
    Qi J; Hu KS; Yang HL
    Int J Clin Exp Pathol; 2015; 8(10):11995-2004. PubMed ID: 26722385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
    Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
    Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival.
    Ochi H; Hara Y; Tagawa M; Shinomiya K; Asou Y
    J Orthop Res; 2010 May; 28(5):657-63. PubMed ID: 19890995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression.
    Brechter AB; Lerner UH
    Arthritis Rheum; 2007 Mar; 56(3):910-23. PubMed ID: 17328065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
    Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
    J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
    Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.
    Rinotas V; Niti A; Dacquin R; Bonnet N; Stolina M; Han CY; Kostenuik P; Jurdic P; Ferrari S; Douni E
    J Bone Miner Res; 2014; 29(5):1158-69. PubMed ID: 24127173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of NF-κB1 prevents bone loss caused by mechanical unloading.
    Nakamura H; Aoki K; Masuda W; Alles N; Nagano K; Fukushima H; Osawa K; Yasuda H; Nakamura I; Mikuni-Takagaki Y; Ohya K; Maki K; Jimi E
    J Bone Miner Res; 2013 Jun; 28(6):1457-67. PubMed ID: 23322687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts.
    Akiyama T; Dass CR; Shinoda Y; Kawano H; Tanaka S; Choong PF
    J Pharm Pharmacol; 2010 Apr; 62(4):470-6. PubMed ID: 20604836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis.
    Leistner DM; Seeger FH; Fischer A; Röxe T; Klotsche J; Iekushi K; Seeger T; Assmus B; Honold J; Karakas M; Badenhoop K; Frantz S; Dimmeler S; Zeiher AM
    Circ Heart Fail; 2012 Nov; 5(6):769-77. PubMed ID: 22936827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.
    Zupan J; Komadina R; Marc J
    J Biomed Sci; 2012 Mar; 19(1):28. PubMed ID: 22380539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression.
    Xie H; Xie PL; Wu XP; Chen SM; Zhou HD; Yuan LQ; Sheng ZF; Tang SY; Luo XH; Liao EY
    Cardiovasc Res; 2011 Nov; 92(2):296-306. PubMed ID: 21750093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.